What is the impact of antiviral treatment for people who inject drugs on the overall number of new hepatitis C infections within the population of injecting drug users?

Evaluating the Population Impact of hepatitis C direct-acting antiviral Treatment as Prevention for people who inject drugs: a non-randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN72038467

Enrollment

500

Registered

2019-01-24

Start date

2019-01-15

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C Infections and Infestations Chronic viral hepatitis C

Interventions

Work stream (WS) 1: the removal of any restrictions of access to treatment by disease stage and scaling-up treatment in PWID. Treatment of hepatitis C (HCV) will be offered to active drug users across

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. HCV diagnosis 2. Injecting drug use 3. Aged 18 years or over

Exclusion criteria

Exclusion criteria: 1. Mental health or behavioural problems e.g. psychosis, aggressiveness.

Design outcomes

Primary

Measure	Time frame
The utility status of HCV infection and the change in utility with treatment and cure will be measured using the EQ5D5L questionnaire at treatment start, treatment end, 12 weeks following end of treatment and one year following treatment.	—

Secondary

Measure	Time frame
1. The experiences and perceptions of service providers will be measured using qualitative interviews and/or focus groups during the latter stages of treatment scale -up during 2018-2019. 2. The experiences and perceptions of individuals undergoing HCV treatment will be measured using qualitative interviews post treatment and around one year later. 3. The experiences and perceptions of individuals refusing HCV treatment will be measured using qualitative interviews once following refusal of treatment.	—

Measure

Time frame

1. The experiences and perceptions of service providers will be measured using qualitative interviews and/or focus groups during the latter stages of treatment scale -up during 2018-2019. 2. The experiences and perceptions of individuals undergoing HCV treatment will be measured using qualitative interviews post treatment and around one year later. 3. The experiences and perceptions of individuals refusing HCV treatment will be measured using qualitative interviews once following refusal of treatment.

—

Countries

Scotland, United Kingdom

Contacts

Public ContactBeth Thorne

beth.thorne@bristol.ac.uk+44 (0)117 331 3320

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 14, 2026